Nested Therapeutics Announces Oral Presentation of Preclinic

Nested Therapeutics Announces Oral Presentation of Preclinical Data for NST-628, a Novel, Fully Brain-Penetrant, Pan-RAF/MEK Molecular Glue, at the 2024 AACR Annual Meeting

Concurrent publication in the journal Cancer Discovery highlights NST-628's differentiated mechanism and preclinical activity across diverse KRAS-, NRAS-, and BRAF-driven tumors

Related Keywords

United States , American , Klaus Hoeflich , Therapeutics Inc , American Association For Cancer Research , Linkedin , Cancer Discovery , American Association , Cancer Research , Fully Brain Penetrant , Molecular Glue , Driven Cancers , Nested Therapeutics ,